Published in Adv Exp Med Biol on January 01, 2010
Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol (2013) 2.64
Toll-like receptor 4 stimulation with the detoxified ligand monophosphoryl lipid A improves Alzheimer's disease-related pathology. Proc Natl Acad Sci U S A (2013) 2.45
Dendritic-cell-based therapeutic cancer vaccines. Immunity (2013) 2.29
Anti-tumour strategies aiming to target tumour-associated macrophages. Immunology (2013) 1.40
Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. Oncoimmunology (2012) 1.30
The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination? Cancer J (2011) 1.19
Antigen-specific bacterial vaccine combined with anti-PD-L1 rescues dysfunctional endogenous T cells to reject long-established cancer. Cancer Immunol Res (2013) 1.15
Toll-like receptor 4 activation in cancer progression and therapy. Clin Dev Immunol (2011) 1.14
Tolerogenic dendritic cell therapy for rheumatoid arthritis: where are we now? Clin Exp Immunol (2013) 1.09
The SSX family of cancer-testis antigens as target proteins for tumor therapy. Clin Dev Immunol (2010) 1.06
MyD88 and TRIF synergistic interaction is required for TH1-cell polarization with a synthetic TLR4 agonist adjuvant. Eur J Immunol (2013) 1.03
Lack of lipid A pyrophosphorylation and functional lptA reduces inflammation by Neisseria commensals. Infect Immun (2012) 1.02
Chitin, chitosan, and glycated chitosan regulate immune responses: the novel adjuvants for cancer vaccine. Clin Dev Immunol (2013) 1.00
Trial Watch: Toll-like receptor agonists in oncological indications. Oncoimmunology (2014) 0.96
Vaccine adjuvants: mode of action. Front Immunol (2013) 0.94
Enhancement of tumor-specific T cell-mediated immunity in dendritic cell-based vaccines by Mycobacterium tuberculosis heat shock protein X. J Immunol (2014) 0.88
Regulatory dendritic cell therapy: from rodents to clinical application. Immunol Lett (2013) 0.87
Platelet-derived growth factor-C (PDGF-C) induces anti-apoptotic effects on macrophages through Akt and Bad phosphorylation. J Biol Chem (2014) 0.86
Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumors. BMC Cancer (2013) 0.84
In vitro and in vivo anticancer activity of a synthetic glycolipid as Toll-like receptor 4 (TLR4) activator. J Biol Chem (2011) 0.83
InCVAX--a novel strategy for treatment of late-stage, metastatic cancers through photoimmunotherapy induced tumor-specific immunity. Cancer Lett (2015) 0.82
Intratumoral delivery of low doses of anti-CD40 mAb combined with monophosphoryl lipid a induces local and systemic antitumor effects in immunocompetent and T cell-deficient mice. J Immunother (2013) 0.82
A unique host defense pathway: TRIF mediates both antiviral and antibacterial immune responses. Microbes Infect (2012) 0.81
Toll-like receptor-4 modulation for cancer immunotherapy. Front Immunol (2014) 0.81
Vaccine adjuvants as potential cancer immunotherapeutics. Int Immunol (2016) 0.80
Malaria vaccine adjuvants: latest update and challenges in preclinical and clinical research. Biomed Res Int (2013) 0.78
Non-clinical safety evaluation of repeated intramuscular administration of the AS15 immunostimulant combined with various antigens in rabbits and cynomolgus monkeys. J Appl Toxicol (2015) 0.78
A Comprehensive Preclinical Model Evaluating the Recombinant PRAME Antigen Combined With the AS15 Immunostimulant to Fight Against PRAME-expressing Tumors. J Immunother (2015) 0.78
Prothymosin α and a prothymosin α-derived peptide enhance T(H)1-type immune responses against defined HER-2/neu epitopes. BMC Immunol (2013) 0.78
Mycobacterium tuberculosis Rv3628 drives Th1-type T cell immunity via TLR2-mediated activation of dendritic cells and displays vaccine potential against the hyper-virulent Beijing K strain. Oncotarget (2016) 0.77
Gene expression profiles identify both MyD88-independent and MyD88-dependent pathways involved in the maturation of dendritic cells mediated by heparan sulfate: a novel adjuvant. Hum Vaccin Immunother (2014) 0.76
Combination of the toll like receptor agonist and α-Galactosylceramide as an efficient adjuvant for cancer vaccine. J Biomed Sci (2016) 0.75
Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT). Ann Oncol (2016) 0.75
From discovery to licensure, the Adjuvant System story. Hum Vaccin Immunother (2016) 0.75
Use of adjuvants for immunotherapy. Hum Vaccin Immunother (2017) 0.75